TRVI vs. ZVRA, DSGN, ACRV, VERU, GTHX, PRLD, ELYM, TELO, LFCR, and QURE
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Zevra Therapeutics (ZVRA), Design Therapeutics (DSGN), Acrivon Therapeutics (ACRV), Veru (VERU), G1 Therapeutics (GTHX), Prelude Therapeutics (PRLD), Eliem Therapeutics (ELYM), Telomir Pharmaceuticals (TELO), Lifecore Biomedical (LFCR), and uniQure (QURE). These companies are all part of the "pharmaceutical preparations" industry.
Trevi Therapeutics (NASDAQ:TRVI) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation.
Trevi Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.
In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 10 articles in the media. Zevra Therapeutics' average media sentiment score of 0.38 beat Trevi Therapeutics' score of -0.30 indicating that Zevra Therapeutics is being referred to more favorably in the news media.
Trevi Therapeutics received 65 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 27.5% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Trevi Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -167.69%. Trevi Therapeutics' return on equity of -31.51% beat Zevra Therapeutics' return on equity.
Trevi Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 191.10%. Zevra Therapeutics has a consensus target price of $19.50, indicating a potential upside of 287.67%. Given Zevra Therapeutics' higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Trevi Therapeutics.
Trevi Therapeutics has higher earnings, but lower revenue than Zevra Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Trevi Therapeutics beats Zevra Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
